VKTX Jonathan Faison @jfais20 $VKTX (NP) $2.1B EV 50M+ patient opportunity ($50B TAM) in obesity Slight improvements to safety & efficacy (even if little clear differentiation) for GLP-1/GIP agonist VK2735 Make Betaville buyout rumor believable (considering that $NVO Wegovy already at $1.4B in Q4 sales.. Kiwi